Oramed Pharmaceuticals Inc.

ORMP

US68403P2039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
2.57 ^USD	-4.10%		+11.74%	+11.26%

26/06	Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program	MT
26/06	Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.	CI

Oramed Pharmaceuticals Inc. authorizes a Buyback Plan.

June 26, 2024

The Board of Directors of Oramed Pharmaceuticals Inc. has authorized a buyback plan on June 26, 2024.

Latest news about Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program	26/06	MT
Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.	26/06	CI
Oramed Pharmaceuticals Inc. authorizes a Buyback Plan.	26/06	CI
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket	12/06	MT
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Chief Financial Officer, Effective as of June 18, 2024	11/06	CI
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024	11/06	CI
Compugen Names David Silberman CFO	15/05	MT
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Chief Financial Officer, Effective July 12, 2024	13/05	CI
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Treasurer and Secretary, Effective July 12, 2024	13/05	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	19/03	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Oramed Pharmaceuticals Inc. Announces Resignation of Yadin Rozov from the Board of Directors	20/01	CI
Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024	19/12	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Oramed Pharmaceuticals Inc.(TASE:ORMP) dropped from TA-125 Index	03/11	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	22/23/22	MT
Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc.	21/23/21	CI
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	21/23/21	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.	07/23/07	CI
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture	02/23/02	MT
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally	02/23/02	CI
Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating	17/23/17	MT
Oramed Pharmaceuticals Says Hefei Tianhui Biotechnology Completes Phase 3 Trial of Oral Insulin; Shares Rise	15/23/15	MT

Chart Oramed Pharmaceuticals Inc.

Duration

Period

More charts

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Sector

Biotechnology & Medical Research

Calendar

10/07/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Oramed Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.57 USD

Average target price

3.25 USD

Spread / Average Target

+26.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORAMED PHARMACEUTICALS INC.	+11.26%	104M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research